{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:22:51Z","timestamp":1794565371711,"version":"4.9.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019139","name":"Life Sciences, University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.dmd.2026.100365","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:21:47Z","timestamp":1784071307000},"page":"100365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["3D hepatic spheroid arrays for clearance assessment of small and bRo5 molecules"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1153-1205","authenticated-orcid":false,"given":"Viraj","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupa","family":"Yellanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parusharamulu","family":"Molgara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesham","family":"Uthukam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhakar Reddy","family":"Kolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi","family":"Madgula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruswamy","family":"Karnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmd.2026.100365_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106853","article-title":"The application of organ-on-chip models for the prediction of human pharmacokinetic profiles during drug development","volume":"195","author":"Keuper-Navis","year":"2023","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.dmd.2026.100365_bib2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1124\/dmd.123.001510","article-title":"The current status and use of microphysiological systems by the pharmaceutical industry: the International Consortium for Innovation and Quality Microphysiological Systems Affiliate Survey and Commentary","volume":"52","author":"Baker","year":"2024","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100365_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124089","article-title":"Validation of a Caco-2 microfluidic chip model for predicting intestinal absorption of BCS Class I-IV drugs","volume":"656","author":"Zhang","year":"2024","journal-title":"Int J Pharm"},{"issue":"9","key":"10.1016\/j.dmd.2026.100365_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100130","article-title":"A primary human gut\/liver microphysiological system to estimate human oral bioavailability","volume":"53","author":"Abbas","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100365_bib5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41551-019-0498-9","article-title":"Quantitative prediction of human drug pharmacokinetic responses using multiple vascularized organ chips coupled by fluid transfer","volume":"4","author":"Herland","year":"2020","journal-title":"Nat Biomed Eng"},{"issue":"2","key":"10.1016\/j.dmd.2026.100365_bib6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1208\/s12248-022-00689-y","article-title":"Multi-well array culture of primary human hepatocyte spheroids for clearance extrapolation of slowly metabolized compounds","volume":"24","author":"Preiss","year":"2022","journal-title":"AAPS J"},{"issue":"9","key":"10.1016\/j.dmd.2026.100365_bib7","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1124\/dmd.112.046425","article-title":"A novel relay method for determining low-clearance values","volume":"40","author":"Di","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100365_bib8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1124\/dmd.113.053397fullarticlecorrection","article-title":"Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac","volume":"47","author":"Chan","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2026.100365_bib9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1124\/dmd.121.000601","article-title":"Reaction phenotyping of low-turnover compounds in long-term hepatocyte cultures through persistent selective inhibition of cytochromes P450","volume":"49","author":"Smith","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2026.100365_bib10","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1021\/acs.molpharmaceut.6b00396","article-title":"Use of H\u03bcREL human coculture system for prediction of intrinsic clearance and metabolite formation for slowly metabolized compounds","volume":"13","author":"Hultman","year":"2016","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.dmd.2026.100365_bib11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1124\/dmd.123.001638","article-title":"Comparison of human long-term liver models for clearance prediction of slowly metabolized compounds","volume":"52","author":"Preiss","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100365_bib12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/dmd.120.000340","article-title":"Primary human hepatocyte spheroids as an in vitro tool for investigating drug compounds with low hepatic clearances","volume":"49","author":"Riede","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2026.100365_bib13","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/dmd.124.001653","article-title":"Evaluation and optimization of a microcavity plate\u2013based human hepatocyte spheroid model for predicting clearance of slowly metabolized drug candidates","volume":"52","author":"Kukla","year":"2024","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100365_bib14","article-title":"A novel milli-fluidic liver tissue chip with continuous recirculation for predictive pharmacokinetics applications","author":"Amala","year":"2023","journal-title":"BioRxiv"},{"issue":"6","key":"10.1016\/j.dmd.2026.100365_bib15","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1039\/D1LC01161H","article-title":"Exploration and application of a liver-on-a-chip device in combination with modelling and simulation for quantitative drug metabolism studies","volume":"22","author":"Docci","year":"2022","journal-title":"Lab Chip"},{"issue":"1","key":"10.1016\/j.dmd.2026.100365_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-pharmtox-061724-080621","article-title":"Opportunities for microphysiological systems in toxicity testing of new drug modalities","volume":"65","author":"Maulana","year":"2025","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100365_bib17","first-page":"469","article-title":"Application of microphysiological systems for nonclinical evaluation of cell therapies","volume":"41","author":"Candarlioglu","year":"2024","journal-title":"ALTEX"},{"issue":"2","key":"10.1016\/j.dmd.2026.100365_bib18","first-page":"293","article-title":"Leveraging microphysiological systems to address challenges encountered during development of oligonucleotide therapeutics","volume":"39","author":"Ramsden","year":"2022","journal-title":"ALTEX"},{"issue":"20","key":"10.1016\/j.dmd.2026.100365_bib19","doi-asserted-by":"crossref","first-page":"11615","DOI":"10.1021\/acs.jmedchem.0c00793","article-title":"Understanding the metabolism of proteolysis targeting chimeras (PROTACs): the next step toward pharmaceutical applications","volume":"63","author":"Goracci","year":"2020","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.dmd.2026.100365_bib20","doi-asserted-by":"crossref","first-page":"9584","DOI":"10.1021\/acs.jmedchem.5c00358","article-title":"In vitro ADME profiling of PROTACs: successes, challenges, and lessons learned from analysis of clinical PROTACs from a diverse physicochemical space","volume":"68","author":"Srivastava","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.dmd.2026.100365_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/srep25187","article-title":"Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease","volume":"6","author":"Bell","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.dmd.2026.100365_bib22","article-title":"Liver-on-chips for drug discovery and development","volume":"27","author":"Mehta","year":"2024","journal-title":"Mater Today Bio"},{"issue":"7","key":"10.1016\/j.dmd.2026.100365_bib23","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1124\/dmd.108.020479","article-title":"Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds","volume":"36","author":"Obach","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2026.100365_bib24","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3109\/00498254.2012.669080","article-title":"Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes","volume":"42","author":"Sohlenius-Sternbeck","year":"2012","journal-title":"Xenobiotica"},{"issue":"11","key":"10.1016\/j.dmd.2026.100365_bib25","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1124\/dmd.118.082966","article-title":"Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 1352 drug compounds","volume":"46","author":"Lombardo","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2026.100365_bib26","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/bcp.14247","article-title":"CYP2D6 polymorphism and its impact on the clinical response to metoprolol: a systematic review and meta-analysis","volume":"86","author":"Meloche","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100365_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100230","article-title":"Influence of 3D architecture and coculture on in vitro CYP enzyme metabolism and induction: benchmarking human hepatic spheroids for studies in drug development","volume":"54","author":"Lenich","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2026.100365_bib28","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1080\/00498250902974229","article-title":"Comparison of intrinsic metabolic clearance in fresh and cryopreserved human hepatocytes","volume":"39","author":"Floby","year":"2009","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.dmd.2026.100365_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/toxsci\/kfae123","article-title":"Physiological liver microtissue 384-well microplate system for preclinical hepatotoxicity assessment of therapeutic small molecule drugs","volume":"203","author":"F\u00e4s","year":"2024","journal-title":"Toxicol Sci"},{"issue":"4","key":"10.1016\/j.dmd.2026.100365_bib30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1124\/dmd.115.067769","article-title":"Determination of human hepatocyte intrinsic clearance for slowly metabolized compounds: comparison of a primary hepatocyte\/stromal cell co-culture with plated primary hepatocytes and HepaRG","volume":"44","author":"Bonn","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2026.100365_bib31","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1124\/dmd.113.053397","article-title":"Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac","volume":"41","author":"Chan","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100365_bib32","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1021\/acs.jmedchem.3c01007","article-title":"Discovery and preclinical pharmacology of NX-2127, an orally bioavailable degrader of Bruton\u2019s tyrosine kinase with immunomodulatory activity for the treatment of patients with B cell malignancies","volume":"67","author":"Robbins","year":"2024","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.dmd.2026.100365_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.101175","article-title":"Characterization of preclinical radio ADME properties of ARV-471 for predicting human PK using PBPK modeling","volume":"15","author":"He","year":"2025","journal-title":"J Pharm Anal"},{"issue":"16","key":"10.1016\/j.dmd.2026.100365_bib34","doi-asserted-by":"crossref","first-page":"14277","DOI":"10.1021\/acs.jmedchem.4c01104","article-title":"Radioactive ADME demonstrates ARV-110\u2019s high druggability despite low oral bioavailability","volume":"67","author":"He","year":"2024","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.dmd.2026.100365_bib35","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.drudis.2020.07.013","article-title":"Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective","volume":"25","author":"Pike","year":"2020","journal-title":"Drug Discov Today"},{"issue":"6","key":"10.1016\/j.dmd.2026.100365_bib36","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.drudis.2020.03.012","article-title":"Fundamental aspects of DMPK optimization of targeted protein degraders","volume":"25","author":"Cantrill","year":"2020","journal-title":"Drug Discov Today"},{"issue":"7","key":"10.1016\/j.dmd.2026.100365_bib37","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1177\/2472555219848483","article-title":"Addition of optimized bovine serum albumin level in a high-throughput Caco-2 assay enabled accurate permeability assessment for lipophilic compounds","volume":"24","author":"Cai","year":"2019","journal-title":"SLAS Discov"},{"issue":"1","key":"10.1016\/j.dmd.2026.100365_bib38","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s43856-022-00209-1","article-title":"Performance assessment and economic analysis of a human liver-chip for predictive toxicology","volume":"2","author":"Ewart","year":"2022","journal-title":"Commun Med"},{"issue":"2","key":"10.1016\/j.dmd.2026.100365_bib39","doi-asserted-by":"crossref","DOI":"10.1063\/1.3576905","article-title":"Hepatocyte spheroid arrays inside microwells connected with microchannels","volume":"5","author":"Fukuda","year":"2011","journal-title":"Biomicrofluidics"},{"issue":"2","key":"10.1016\/j.dmd.2026.100365_bib40","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/toxsci\/kfx289","article-title":"Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study","volume":"162","author":"Bell","year":"2018","journal-title":"Toxicol Sci"},{"issue":"1","key":"10.1016\/j.dmd.2026.100365_bib41","first-page":"G12","article-title":"Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration","volume":"277","author":"Liu","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.dmd.2026.100365_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114719","article-title":"A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats","volume":"211","author":"Niessen","year":"2025","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.dmd.2026.100365_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1694436","article-title":"Navigating hepatotoxicity of antibody-drug conjugates: from mechanistic insights to clinical and postmarketing evidence","volume":"16","author":"Dong","year":"2025","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100365_bib44","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/dmd.121.000418","article-title":"Adverse drug reactions and toxicity of the food and drug administration-approved antisense oligonucleotide drugs","volume":"50","author":"Alhamadani","year":"2022","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:20:13Z","timestamp":1794561613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0090955626006343"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100365","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3D hepatic spheroid arrays for clearance assessment of small and bRo5 molecules","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100365","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100365"}}